Summary
Harvest fluid derived from a primary hepatocellular carcinoma cell line (PLC/PRF/5) inhibited the incorporation of 3H-thymidine into PHA-activated human lymphocytes. A similar effect was observed when lymphocytes were pre-incubated with the tumour supernatant and washed prior to mitogen activation. Not only did the tumour supernatant inhibit 3H-thymidine incorporation by mitogen-activated lymphocytes, but it also inhibited production of the lymphokine leucocyte inhibitory factor (LIF). In experiments designed to establish whether a component of the tumour harvest fluid was activating a population of suppressor cells, normal mononuclear (MN) cells were treated with the PLC/PRF/5 or embryonic fibroblast supernatant for 48 h, after which they were washed and added to normal mitogen-activated lymphocyte cultures. Only cells pretreated with the PLC/PRF/5 supernatant suppressed mitogenesis. The cell responsible for the suppressor effect was a T cell, which after a further 24 h in culture liberated a suppressor factor responsible for inhibiting lymphocyte function. Although the nature of the factor/s in the PLC/PRF/5 supernatant responsible for activation of the T-suppressor cell population is unknown, it is suggested that this mechanism may be important in protecting the tumour from the immune response.
Similar content being viewed by others
References
Badger AM, Oh SK, Moolten FR (1981) Differential effects of an immunosuppressive fraction from ascites fluids of patients with ovarian cancer on spontaneous and antibody-dependent cytotoxicity. Cancer Res 41:1133
Eremin O (1980) NK cell activity in the blood, tumour-draining lymph nodes and primary tumours of women with mammary carcinoma. In: Herberman RB (ed) Natural cell-mediated immunity against tumours. Academic Press, New York, pp 1011–1030
Giuliano AE, Rangel D, Golub SH, Homes EC, Morton DL (1979) Serum-mediated immunosuppression in lung cancer. Cancer 43:917
Glasgow AH, Nimberg RB, Menzoian JO, Saporoschetz I, Cooperband SR, Schmid K, Mannick JA (1974) Association of anergy with an immunosuppressive peptide fraction in the serum of patients with cancer. N Engl J Med 291:1263
Hersh EM, Drewinko B (1974) Specific inhibition of lymphocyte blastogenic responses to mitogens by a factor produced by cultured human malignant lymphoma cells. Cancer Res 34:215
Hersh EM, McCredie KB, Freireich EJ (1974) Inhibition of in vitro lymphocyte blastogenesis by an inhibitor produced by cultured human lymphoblasts. Clin Exp Immunol 17:463
Kamo I, Friedman H (1977) Immunosuppression and the role of suppressive factors in cancer. Adv Cancer Res 25:271
Keong A, Hermann J, Rabson AR (1983) Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) depresses natural killer (NK) cell activity. Cancer Immunol Immunother (in press)
Mohaghephpour N, Parhami B, Dowlatshaki K, Kadjehnouri D, Elder JH, Chisari FV (1979) Immunoregulatory properties of human oesophageal tumour extract. J Immunol 122:1350
Renk CM, Gupta RK, Morton DL (1981) Inhibition of normal allogeneic lymphocyte mitogenesis by a factor released from human tumour cells in culture. Cancer Immunol Immunother 11:7
Roth JA, Grimm EA, Gupta RK, Ames RS (1982) Immunoregulatory factors derived from human tumours. J Immunol 128:1955
Tanaka F, Yonemoto RH, Waldmann SR (1979) Blocking factors in the sera of breast cancer patients. Cancer 43:838
Vose BM, Moore M (1979) Suppressor cell activity of lymphocytes infiltrating human lung and breast tumours. Int J Cancer 24:579
Werkmeister J, Zbroja R, McCarthy W, Hersey P (1980) Detection of an inhibitor of cell division in cultures of tumour cells with immunosuppressive activity in vitro. Clin Exp Immunol 40:168
Whitehead JS, Kim YS (1980) An inhibitor of lymphocyte proliferation produced by a human colonic adenocarcinoma cell line in culture. Cancer Res 40:29
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Keong, A., Rabson, A.R. Supernatant derived from a human hepatocellular carcinoma cell line (PLC/PRF/5) activates a population of T-suppressor cells. Cancer Immunol Immunother 15, 178–182 (1983). https://doi.org/10.1007/BF00199161
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00199161